Literature DB >> 11834403

Cavernous and systemic plasma levels of norepinephrine and epinephrine during different penile conditions in healthy men and patients with erectile dysfunction.

Armin J Becker1, Stefan Uckert, Christian G Stief, Friedemann Scheller, Wolfram H Knapp, Uwe Hartmann, Udo Jonas.   

Abstract

OBJECTIVES: To examine and compare the courses of norepinephrine (NE) and epinephrine (E) plasma levels in the systemic and cavernous blood taken during different penile conditions from healthy men and a group of patients with erectile dysfunction (ED). Knowledge concerning the neurophysiology of penile erection has improved tremendously during the past two decades. However, only few in vivo studies on human peripheral neurotransmission have been carried out to date.
METHODS: Fifty-three healthy adult male subjects and 47 patients with ED of different etiologies were exposed to erotic stimuli to elicit penile tumescence and, in the group of healthy subjects, rigidity. Whole blood was simultaneously aspirated from the corpus cavernosum and the cubital vein during different penile conditions. Plasma levels of NE and E were determined by means of a radioimmunoassay.
RESULTS: In the healthy subjects, a significant reduction of NE in cavernous plasma was detected from flaccidity (362 +/- 173 pg/mL) to rigidity (248 +/- 122 pg/mL), followed by an increase in the detumescence phase (336 +/- 199 pg/mL). Changes in NE levels in the peripheral plasma were less pronounced. Cavernous E levels significantly increased from flaccidity (47 +/- 41 pg/mL) to tumescence (130 +/- 106 pg/mL) and dropped from rigidity (113 +/- 67 pg/mL) to detumescence (76 +/- 57 pg/mL). The course of systemic E plasma levels was similar to that in the cavernous blood. In contrast, median NE levels in the systemic and cavernous blood of the ED group slightly increased from flaccidity to tumescence (from 199 +/- 88 pg/mL to 210 +/- 99 pg/mL and from 273 +/- 140 pg/mL to 278 +/- 118 pg/mL, respectively).
CONCLUSIONS: In healthy men, penile erection is accompanied by a reduction of NE in the cavernous blood and a rise in E levels in the peripheral and cavernous blood. That NE levels in the cavernous and systemic blood increase during sexual arousal in patients with ED might be an indication of a somatic dysregulation in sympathetic transmission or alterations of NE reuptake mechanisms as a cause of impaired erectile function.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11834403     DOI: 10.1016/s0090-4295(01)01521-7

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  6 in total

Review 1.  [Therapy for organic erectile dysfunction].

Authors:  A J Becker; M Mayer; C G Stief
Journal:  Urologe A       Date:  2005-10       Impact factor: 0.639

2.  The effects of age and streptozotocin diabetes on the sympathetic innervation in the rat penis.

Authors:  J F B Morrison; D J Pallot; R Sheen; S Dhanasekaran; E P K Mensah-Brown
Journal:  Mol Cell Biochem       Date:  2006-08-31       Impact factor: 3.396

3.  Sildenafil citrate and tamsulosin combination is not superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction.

Authors:  Altug Tuncel; Varol Nalcacioglu; Kemal Ener; Yilmaz Aslan; Omur Aydin; Ali Atan
Journal:  World J Urol       Date:  2009-10-24       Impact factor: 4.226

4.  Three-Dimensional Proteome-Wide Scale Screening for the 5-Alpha Reductase Inhibitor Finasteride: Identification of a Novel Off-Target.

Authors:  Silvia Giatti; Alessandro Di Domizio; Silvia Diviccaro; Eva Falvo; Donatella Caruso; Alessandro Contini; Roberto Cosimo Melcangi
Journal:  J Med Chem       Date:  2021-04-12       Impact factor: 7.446

Review 5.  Alfuzosin for the medical treatment of benign prostatic hyperplasia and lower urinary tract symptoms: a systematic review of the literature and narrative synthesis.

Authors:  Andrea Mari; Alessandro Antonelli; Luca Cindolo; Ferdinando Fusco; Andrea Minervini; Cosimo De Nunzio
Journal:  Ther Adv Urol       Date:  2021-04-12

6.  Outcomes and quality of life issues in the pharmacological management of benign prostatic hyperplasia (BPH).

Authors:  Angelo J Cambio; Christopher P Evans
Journal:  Ther Clin Risk Manag       Date:  2007-03       Impact factor: 2.423

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.